Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer.

Background Growth of selected castration-resistant prostate cancer (CRPC) cell lines and animal models can be repressed by reexposure to androgens. Low doses of androgens, however, can stimulate tumor growth.